# **MEDICAL DEVICE REIMBURSEMENT**

PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013

Presented by: Michael A. Sanchez, M.A., CCA Principal Advisor +1 (651) 426-3084 info@pivotalreimbursement.com

> Pivotal Reimbursement Consulting www.pivotalreimbursement.com

**COPYRIGHT PIVOTAL REIMBURSEMENT 2013** 

#### MICHAEL A. SANCHEZ, M.A., CCA

#### Principal, Pivotal Reimbursement Consulting

Mike Sanchez is Principal Advisor at Pivotal Reimbursement Consulting, an experienced reimbursement consultancy providing expert strategy, advice and support services to medical device, diagnostic and clinical research clients. Mike has more than 17 years working in the medical device industry. He was previously Manager, Reimbursement & Outcomes Planning at St. Jude Medical, Corporate Reimbursement and Health Policy. Prior to that, he was Principal Advisor at Boston Scientific, Health Economics and Reimbursement. Mike also holds a Master's degree in Management from the College of St. Scholastica, and is a Certified Coding Associate (CCA) through the American Health Information Management Association (AHIMA).

# DISCLAIMER

The reimbursement information provided in this presentation is gathered from third-party sources and is presented for illustrative purposes only. This information does not constitute reimbursement or legal advice. The presenter makes no representation or warranty regarding this information or its completeness, accuracy, timeliness, or applicability with a particular patient. Further, the presenter disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this presentation.

## TOPICS

U.S. Healthcare System Overview
 Coverage Policy, Coding/ Payment Systems
 Reimbursement Assessment of New Technologies
 Strategy Development/ Planning
 Wrap-up/ Q&A

### **UNITED STATES**

The U.S. healthcare system, a blend of multiple public payers and private third party payers, <u>represents a manufacturer's</u> <u>largest market opportunity for most products</u> and has the most stakeholders impacting the reimbursement process...

Manufacturers must understand the payer mix for their product...to assure that the reimbursement strategy aligns to the particular payer sector that will be the most prominent decision-maker.

Source: Global Trends in Reimbursement of Medical Technology (Clinica Reports, CBS948, July 2007):

### THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS)

- CMS administers the Medicare and Medicaid programs, which provides health care to almost <u>one in every three</u> Americans.
- Medicare provides health insurance for more than 44.6 million elderly (> 65 years) and disabled Americans.
- Medicaid program provides health coverage for some 50 million low-income persons, including 24 million children, and nursing home coverage for low-income elderly.

### **U.S. REIMBURSEMENT SYSTEMS OVERVIEW**

The key components for successful Medicare and commercial payer reimbursement include Coverage, Coding and Payment

All three of these elements are essential if adequate reimbursement is to be obtained for a new medical device technology.

For example, just because a discrete code is available, it does not mean a procedure will be covered or paid appropriately.

Source: Innovators' Guide to Navigating Medicare (Version 2.0, 2010): http://www.cms.gov/Medicare/Coverage/CouncilonTechInnov/downloads/InnovatorsGuide5\_10\_10.pdf

#### WHAT IS "REIMBURSEMENT"?

Three distinct elements: Coverage + Coding = Payment

#### Coverage

The criteria under which a product, service or procedure will be paid (NCD, LCD)

#### Payment

The amount paid for a product, service or procedure (MS-DRG, APC, PFS)

#### Coding

Mechanism by which a product, service or procedure is identified (CPT, ICD-9)

### COVERAGE

The vast majority of coverage policy is determined on a local level by the Medicare contractors that pay Medicare claims (i.e., not by written coverage policy but on a per-claim basis).

For any item to be covered by Medicare, it must first:

- be eligible for a defined Medicare benefit category;
- be <u>reasonable and necessary</u> for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member; and,
- meet all other applicable Medicare statutory and regulatory requirements.

FDA approval does not guaranty CMS coverage

#### **CMS NATIONAL AND LOCAL COVERAGE**

#### National Coverage Determination (NCD)

• In certain cases, Medicare deems it appropriate to develop criteria for coverage via a national coverage determinations

#### Local Coverage Determination (LCD)

 Medicare administrative contractor (MAC) develops Local Coverage Determination that apply only within the jurisdiction served by the individual contractor.

### **CODING SYSTEMS OVERVIEW**

ICD-9-CM codes consists of codes for diagnoses and for hospital inpatient procedures.

- **ICD-9-CM Volume 1 contains the diagnosis codes** that every health care provider needs for billing (Volume 2 is an alphabetical index of Volume 1).
- **Volume 3 contains procedure codes**, which are used for billing inpatient hospital stays in the Medicare Severity-Diagnosis Related Group (MS-DRG).

**Note**: a new and much different ICD-10 system is scheduled for implementation on Oct. 1, 2014

### **CODING SYSTEMS OVERVIEW**

**CPT-4 codes:** Used to describe both physician (all service sites) and "outpatient" hospital services:

- The two main types of CPT codes include Category I (Permanent) codes and Category III (Emerging technology) codes
  - "Close to" is not good enough -- If no existing CPT code matches a new service, then providers must use "unlisted" codes

Level II HCPCS codes: Level II HCPCS codes are used primarily to identify products and services not included in the CPT codes:

Such as drugs and biologicals, or durable medical equipment (E.g., Device Product Category "C-codes")

### MEDICARE PAYMENT

#### **Hospital Payment Systems**

Once coding and coverage are established, hospital payment is assigned depending upon the site of service the procedure is performed.

#### **Physician Payments**

- Physicians are paid on a per-procedure basis, as indicated using CPT codes.
- Each CPT code has a relative weighting from which the reimbursement amount can be derived.

Source: Innovators' Guide to Navigating Medicare (Version 2.0, 2010): www.cms.gov/Medicare/Coverage/CouncilonTechInnov/downloads/InnovatorsGuide5 10 10.pdf

### **MEDICARE PAYMENT**

Medicare pays for most items and services on a prospective rather than cost basis. A prospective, fixed payment system allows for better resource planning by providers, offers bundled services or items for care management, and provides incentives for efficiencies.

**Medicare Payment System Summary:** 

Medicare-Severity Diagnosis Related Groups (MS-DRG)
 Specific to Inpatient hospital admissions under IPPS
 One bundled payment per admission based on patient conditions, severity of conditions, and procedures performed

Source: Innovators' Guide to Navigating Medicare (Version 2.0, 2010): www.cms.gov/Medicare/Coverage/CouncilonTechInnov/downloads/InnovatorsGuide5\_10\_10.pdf

### **MEDICARE PAYMENT**

2) Ambulatory Payment Classifications (APC)
Specific to outpatient hospital encounters
One or more payments per encounter based on number of procedures performed
Subject packaging rules and multiple discounting
3) Physician Fee Schedule (PFS)
Specific to professional provider services (All sites of service)
One or more payments per encounter based on number of procedures performed

### **REIMBURSEMENT: WHAT IS ISN'T?**

#### Something to think about just before product launch

- Assessment best performed at concept then carried forward throughout the product lifecycle
  - The external reimbursement landscape is in constant flux and must be continuously monitored from concept on through market maturity
- Less important than other assessments
  - The stakes are high and have equal importance to other crossfunctional assessments and strategic planning efforts!!!

Any gaps or delays in the coverage, coding, or payment landscape <u>has a direct impact on new product adoption</u>

#### **REIMBURSEMENT STRATEGY**

#### 1. Identify competing products

Are there comparable devices on the market?
 Who will be first to market? When? (clinicaltrials.gov)
 First to market company tends to pave the reimbursement landscape
 Determine reimbursement gaps, risks, and opportunities
 What is the current coding/coverage/payment landscape?
 What changes to this landscape are anticipated?
 E.g., The Accountable Care Act (aka Obama-Care)
 Is there potential value to the healthcare system
 E.g., more effective/ less expensive

### REIMBURSEMENT STRATEGY

3. Develop internal strategies to address gaps, mitigate risks, and leverage opportunities

What data needs to generated or collected and when?

E.g., Cost and utilization data during pivotal trial

What internal resources will be needed and planned for?

E.g., Dedicated team and budget

What outside support support is required?

Consulting expertise often needed to change reimbursement

### **QUESTIONS?**

# Thank you!

#### CONTACT

Michael A. Sanchez, M.A., CCA Principal Advisor Pivotal Reimbursement Consulting Phone: +1 (651) 426-3084 Email: info@PivotalReimbursement.com PIVOTAL REIMBURSEMENT CONSULTING www.pivotalreimbursement.com

Committed to helping your company make intelligent, informed decisions that includes sound reimbursement advice

PRC is an experienced reimbursement consultancy providing expert strategy, advice and support services to medical device, diagnostic and clinical research clients